

### Lifetime Probability of Developing and Dying from Cancer, 2015-2017

	MALES				FEMALES			
	Developing		Dying		Developing		Dying	
	%	1 in...	%	1 in...	%	1 in...	%	1 in...
<b>All Sites*</b>	40.5	2	20.9	5	38.9	3	18.1	6
Brain & ONS	0.7	145	0.5	189	0.5	182	0.4	238
Breast	0.1	748	<0.1	3,242	12.9	8	2.5	39
Colorectal	4.3	23	1.8	56	4.0	25	1.6	61
Esophagus	0.8	126	0.7	134	0.2	429	0.2	511
Hodgkin lymphoma	0.2	433	<0.1	2,687	0.2	515	<0.1	3,561
Kidney & renal pelvis	2.2	46	0.6	170	1.3	80	0.3	308
Larynx	0.5	194	0.2	547	0.1	812	<0.1	2,160
Leukemia	1.8	55	0.9	106	1.3	78	0.7	149
Liver & intrahepatic bile duct	1.5	69	1.0	97	0.6	161	0.5	184
Lung & bronchus	6.6	15	5.2	19	6.0	17	4.3	23
Melanoma of skin†	3.7	27	0.4	225	2.5	40	0.2	450
Myeloma	1.0	105	0.5	215	0.7	139	0.4	269
Non-Hodgkin lymphoma	2.4	42	0.8	125	1.9	52	0.6	161
Oral cavity & pharynx	1.7	60	0.4	238	0.7	141	0.2	533
Ovary	--	--	--	--	1.2	82	0.9	116
Pancreas	1.7	60	1.4	71	1.6	62	1.4	74
Prostate	12.1	8	2.4	41	--	--	--	--
Stomach	1.0	96	0.4	232	0.7	151	0.3	341
Testis	0.4	247	<0.1	5,040	--	--	--	--
Thyroid	0.7	146	0.1	1,697	1.9	53	0.1	1,436
Urinary bladder‡	3.8	26	0.9	108	1.2	86	0.3	288
Uterine cervix	--	--	--	--	0.6	158	0.2	455
Uterine corpus	--	--	--	--	3.1	32	0.6	156

\*All sites excludes basal cell and squamous cell skin cancers and in situ cancers except urinary bladder.

†Statistics are for non-Hispanic whites.

‡Includes invasive and in situ cancer cases.

**Source:** Software: DevCan: Probability of Developing or Dying of Cancer Software, Version 6.7.8, National Cancer Institute, 2020.